Showing results out of
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
SCIENCE & TECHNOLOGY2023
sciencescience-technology
By screening hundreds of sybodies (synthetic mini-antibodies), scientists have identified one that might stop SARS-CoV-2 from infecting human cells. This work, which holds promise for treating COVID-19, was conducted by EMBL Hamburg and collaborators from the Centre for Structural Systems Biology…
SCIENCE & TECHNOLOGY2020
sciencescience-technology
Scientists hope that a legacy of the novel coronavirus in recovered COVID-19 patients – antibodies in their blood – could lead to drugs to treat others. The Merten group at EMBL Heidelberg has pivoted its microfluidics platform to support the search for neutralising antibodies that could…
SCIENCE & TECHNOLOGY2020
sciencescience-technology
Scientists at EMBL Hamburg and Karolinska Institutet Stockholm aim to find synthetic antibodies – known as nanobodies – that bind a surface protein of the novel SARS-CoV-2 coronavirus. Nanobodies could prevent the virus from entering human cells and causing COVID-19.
SCIENCE & TECHNOLOGY2020
sciencescience-technology
The new EMBL spinoff company Araxa Biosciences GmbH aims to set new standards for the development of antibody-based therapeutics and diagnostics
LAB MATTERSSCIENCE & TECHNOLOGY2020
lab-mattersscience-technology
New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies
LAB MATTERSSCIENCE & TECHNOLOGY2018
lab-mattersscience-technology
No results found